LBA43 GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)

Yi‐Long Wu, Jing Yang, Ou Jiang et al.|Annals of Oncology|2021

Cited by 6